Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
age
blast cell count
chronic myelomonocytic leukaemia
cytogenetics
mutations
score
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
02
05
2021
received:
02
03
2021
accepted:
04
05
2021
pubmed:
18
5
2021
medline:
25
12
2021
entrez:
17
5
2021
Statut:
ppublish
Résumé
In older patients with chronic myelomonocytic leukaemia (CMML) and limited life expectancy due to age and or comorbidities, it is particularly important to consider the risk of transformation for individualised treatment decisions. There is limited information on potential differences between younger and older CMML patients regarding the cumulative risk of transformation as well as haematological, molecular and biologic characteristics. We analysed data from the Austrian Biodatabase for CMML (ABCMML) to compare these parameters in 518 CMML patients. Categorisation of patients into 3 age-related groups: <60 years, 60-79 years and ≥80 years, showed a significantly lower risk of transformation at higher age by competing risk analysis, with a 4-year risk of 39%, 23% and 13%, respectively (P < .0001). The lower probability of transformation was associated with a lower percentage of blast cells in the peripheral blood (PB) of older patients. Furthermore, we provide a simple score based on age, PB blasts and platelet counts that allowed us to define subgroups of CMML patients with a different cumulative transformation risk, including a low-risk group with a transformation risk of only 5%. Our findings may facilitate reasonable treatment decisions in elderly patients with CMML.
Identifiants
pubmed: 33998054
doi: 10.1111/ejh.13647
pmc: PMC8480146
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-274Subventions
Organisme : Gesellschaft zur Erforschung der Biologie und Therapie von Tumorkrankheiten
ID : ABCMML-112015
Organisme : Austrian Science Fund (FWF)
ID : SFB F4704-B20
Informations de copyright
© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Lancet Haematol. 2021 Feb;8(2):e135-e148
pubmed: 33513373
Eur J Haematol. 2021 Aug;107(2):265-274
pubmed: 33998054
Haematologica. 2006 Dec;91(12):1596-604
pubmed: 17145595
Haematologica. 2011 Mar;96(3):375-83
pubmed: 21109693
Leukemia. 2018 May;32(5):1264-1266
pubmed: 29483710
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2014 Nov;28(11):2206-12
pubmed: 24695057
Int J Lab Hematol. 2020 Aug;42(4):418-422
pubmed: 32297416
Wien Klin Wochenschr. 2019 Sep;131(17-18):410-418
pubmed: 31321531
Cancer. 2007 Feb 15;109(4):713-7
pubmed: 17219444
Am J Hematol. 2014 Dec;89(12):1111-5
pubmed: 25195656
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Haematologica. 2019 Oct;104(10):1935-1949
pubmed: 31048353
Blood. 2002 Feb 1;99(3):840-9
pubmed: 11806985
Blood. 2002 Oct 1;100(7):2292-302
pubmed: 12239137
Blood Cancer J. 2015 Jan 02;5:e270
pubmed: 25555161
Curr Opin Hematol. 2015 Mar;22(2):163-70
pubmed: 25575034
Blood. 2006 May 1;107(9):3481-5
pubmed: 16455952
Blood. 2013 Apr 11;121(15):3005-15
pubmed: 23372164
Blood Cancer J. 2015 Jul 31;5:e333
pubmed: 26230957
J Clin Oncol. 2013 Jul 1;31(19):2428-36
pubmed: 23690417
Blood. 2016 Sep 8;128(10):1408-17
pubmed: 27385790
J Exp Med. 1996 Oct 1;184(4):1377-84
pubmed: 8879210
Blood. 1996 Oct 1;88(7):2480-7
pubmed: 8839839
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059439
Br J Haematol. 1982 Jun;51(2):189-99
pubmed: 6952920
Leukemia. 2013 Jul;27(7):1504-10
pubmed: 23531518
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
Leukemia. 1992 Jan;6(1):52-9
pubmed: 1736014
Oncologist. 2017 Mar;22(3):335-342
pubmed: 28220025